B+
Bull case
25%
Probability
Target price
$88.00
+46.9% vs current
GRAL
GRAILBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$64.00
+6.8% vs current
B-
Bear case
30%
Probability
Target price
$42.00
-29.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-15
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+50.7
Score
AI commentary
Primary-source evidence is solid, but external confirmation is thin: the setup is dominated by SEC-filed operating and clinical milestones rather than broad post-print news flow. Price at $61.8 on May 14, 2026 remains well below the packet median target, yet the low catalyst-density prior and lack of robust recent revision data argue for a cautious monitoring posture instead of a strong directional call.
RankAlpha Sentiment Codex - 2026-05-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-30eventLate-breaking ASCO presentations from NHS-Galleri and PATHFINDER 2High impact
GRAIL said detailed NHS-Galleri results will be presented on May 30, 2026 and final PATHFINDER 2 results on May 31, 2026 at ASCO, extending the evidence base behind Galleri and the January 2026 PMA submission; strong read-through could improve confidence in clinical utility and commercial adoption, while mixed detail would reinforce the current monitoring stance [#8-K-2026-05-05].
2026-12-31eventEpic EHR integration could widen physician access by year-end 2026High impact
GRAIL announced planned integration of Galleri into Epic Aura, with broad availability expected by the end of 2026; if implementation reaches large health systems on schedule, ordering friction could fall and help sustain volume growth beyond early-adopter channels [#8-K-2026-05-05].
2027-06-30catalystGalleri PMA review and reimbursement path remain the main rerating driverHigh impact
Management has submitted a PMA for Galleri and is pursuing broader access, but the company states Galleri is not approved or cleared by the FDA and that PMA approval can take several months or years, if at all; any positive regulatory progress would matter more than routine operating updates [#10-Q-2026-05-07] [#10-K-2026-03-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-15 • Updated nightlySource: Internal modelMethodology